Skip to main content
. Author manuscript; available in PMC: 2021 Apr 1.
Published in final edited form as: Invest New Drugs. 2019 May 7;38(2):457–467. doi: 10.1007/s10637-019-00783-7

Fig. 1.

Fig. 1

Overview of GSK3052230 dose-levels and observed dose-limiting toxicities (DLTs). At all dose-levels, the backbone chemotherapy was pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 every 21 days. GSK, GSK3052230; G, grade